News
Boehringer bets up to $500m on Sitryx immunology programme
Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.
News
Lilly says orforglipron tops Wegovy pill in diabetes trial
Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral Wegovy in type 2 diabetes raises as many questions as it answers.
News
Asahi Kasei buys antiviral firm Aicuris for €780m
Asahi Kasei has agreed to buy Germany's Aicuris for around $920m, adding an antiviral drug it hopes will help drive its 2030 pharma sales to $1.9bn.
News
Changes at the top of Sarepta, Alkermes, as CEOs depart
Two long-serving pharma CEOs have announced their departures, as Sarepta's Doug Ingram and Alkermes' Richard Pops announce their retirement.
News
Novo Nordisk beefs up in oral obesity drugs with Vivtex deal
Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
